Brise Pharmaceuticals, which specializes in cutting-edge pain management strategies for both acute and chronic conditions, has secured nearly USD 20 million in pre-Series A and pre-Series A+ funding.
With the backing of Cnfuel Capital, Vinner Therapeutics, and current investors Qiming Venture Partners and BioTrack Capital, Shunxi Fund led the pre-Series A financing. The pre-Series A+ round’s sole investor was Sherpa Healthcare Partners.
Read also – Singapore-Based SWAT Mobility Raises $7.2 Million in Funding
In addition to validating and improving its medication development platforms, Brise said in a statement that it will utilize the cash to progress its product pipeline through the preclinical and clinical stages.
Read also – India-Based Stoxkart Secured $11.9 Million in Funding
In the US and China, Brise has brought two compounds closer to the clinical stage. The money raised will go toward refining and validating the biology-based drug development platforms for the Dorsal Root Ganglion and Trigeminovascular System, as well as advancing the company’s product pipeline in the preclinical and clinical stages.
With a focus on developing novel and highly differentiated analgesic treatments for debilitating pain conditions with significant unmet needs, Brise, led by CEO Dr. Guochun Li, is a clinical-stage biopharmaceutical company with a special emphasis on treating musculoskeletal, neuropathic, and migraine pain.
The goal of the organization is to help the many patients throughout the world who struggle with inadequately managed pain conditions by offering safe, efficient, and easily available pain treatment alternatives.
About Brise Pharma
As a clinical stage biopharmaceutical firm, Brise Pharma focuses primarily on creating novel and very distinctive therapy options for severe pain problems, particularly for migraine, inflammatory pain, and neuropathic pain.
